NCT01747486View on ClinicalTrials.gov

Dose Optimization Trial of CD19 Redirected Autologous T Cells

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 2, 2013

Primary Completion Date

December 13, 2017

Study Completion Date

April 6, 2018

Conditions
Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
Interventions
BIOLOGICAL

CART-19

CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)

Trial Locations (1)

19104

Abramsonc Cancer Center of The University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER

NCT01747486 - Dose Optimization Trial of CD19 Redirected Autologous T Cells | Biotech Hunter | Biotech Hunter